Compare abrdn Income Credit Strategies Fund (ACP) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Inovio Pharmaceuticals Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.15 (market cap $641.16M), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: abrdn Income Credit Strategies Fund is far larger — about 8.2× Inovio Pharmaceuticals Inc's market cap, and abrdn Income Credit Strategies Fund pays a 18.2% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ACP | INO | |
|---|---|---|
Market Cap | $641.16M | $78.55M |
Sector | Financials | Health |
52-Week High | $5.98 | $2.87 |
52-Week Low | $5.01 | $0.66 |
Dividend Yield | 18.2% | — |
Enterprise Value | — | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.14, up 1.18% today, with a neutral technical signal and bearish moving averages. The stock shows strong profitability with a net income margin of 95.31% and a low P/E of 7.74, though revenue declined to $42.46M in 2025 from $79M in 2024. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns.
The outlook is mixed: attractive valuation and high dividends offer income appeal, but revenue volatility and high leverage pose risks. Analyst sentiment is cautious due to unsustainable distribution rates and tight credit spreads, requiring careful monitoring of earnings and credit conditions for future performance.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
